These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33664600)

  • 1. Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma.
    Al-Humimat G; Marashdeh I; Daradkeh D; Kooner K
    J Exp Pharmacol; 2021; 13():197-212. PubMed ID: 33664600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy.
    Wang J; Wang H; Dang Y
    Ophthalmol Ther; 2023 Dec; 12(6):2943-2957. PubMed ID: 37837578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
    Honjo M; Tanihara H
    Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey.
    Singh K; Singh A
    J Curr Glaucoma Pract; 2023; 17(1):44-48. PubMed ID: 37228304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
    Abbhi V; Piplani P
    Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ROCK (RHO-KINASE INHIBITORS) FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION].
    Hayat H; Achiron A; Masarwa D; Goldberg M
    Harefuah; 2023 Mar; 162(3):160-164. PubMed ID: 36966373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.
    Saha BC; Kumari R; Kushumesh R; Ambasta A; Sinha BP
    Int Ophthalmol; 2022 Jan; 42(1):281-294. PubMed ID: 34453229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho/Rho-associated kinase pathway in glaucoma (Review).
    Wang J; Liu X; Zhong Y
    Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
    Rao PV; Pattabiraman PP; Kopczynski C
    Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
    Jethva J; Bhagat P; Prajapati K; Tank G
    Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rho-associated kinase inhibitors: a novel glaucoma therapy.
    Inoue T; Tanihara H
    Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date.
    Dasso L; Al-Khaled T; Sonty S; Aref AA
    Clin Ophthalmol; 2018; 12():1939-1944. PubMed ID: 30323550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho-kinase inhibitors in the management of glaucoma.
    Berrino E; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.
    Sharif NA
    Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
    Araie M; Sugiyama K; Aso K; Kanemoto K; Iwata R; Hollander DA; Senchyna M; Kopczynski CC
    Adv Ther; 2023 Oct; 40(10):4639-4656. PubMed ID: 37603205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].
    Erb C; Konieczka K
    Ophthalmologe; 2021 May; 118(5):449-460. PubMed ID: 33403458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
    Lin CW; Sherman B; Moore LA; Laethem CL; Lu DW; Pattabiraman PP; Rao PV; deLong MA; Kopczynski CC
    J Ocul Pharmacol Ther; 2018; 34(1-2):40-51. PubMed ID: 28609185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.